KR20240056664A - 종양 치료용 항-ｂ7-ｈ1 항체 - Google Patents

종양 치료용 항-ｂ7-ｈ1 항체 Download PDF

Info

Publication number
KR20240056664A
KR20240056664A KR1020247013414A KR20247013414A KR20240056664A KR 20240056664 A KR20240056664 A KR 20240056664A KR 1020247013414 A KR1020247013414 A KR 1020247013414A KR 20247013414 A KR20247013414 A KR 20247013414A KR 20240056664 A KR20240056664 A KR 20240056664A
Authority
KR
South Korea
Prior art keywords
medi4736
antigen
binding fragment
tumor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247013414A
Other languages
English (en)
Korean (ko)
Inventor
라제시 나르왈
데이빗 페어만
풀 로빈스
마이나 리앙
아미 슈나이더
카를로스 샤베츠
카리나 헤를
민 팍
홍 루
마를론 레벨라토
케이트 스틸
안마리 보우트린
리 쉬
쉥얀 홍
브랜든 히그스
로린 로스코스
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20240056664A publication Critical patent/KR20240056664A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247013414A 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체 Ceased KR20240056664A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361876509P 2013-09-11 2013-09-11
US61/876,509 2013-09-11
US201461971212P 2014-03-27 2014-03-27
US61/971,212 2014-03-27
US201461978401P 2014-04-11 2014-04-11
US61/978,401 2014-04-11
US201462003349P 2014-05-27 2014-05-27
US62/003,349 2014-05-27
KR1020227040760A KR102661249B1 (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체
PCT/EP2014/069425 WO2015036499A1 (en) 2013-09-11 2014-09-11 Anti-b7-h1 antibodies for treating tumors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227040760A Division KR102661249B1 (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체

Publications (1)

Publication Number Publication Date
KR20240056664A true KR20240056664A (ko) 2024-04-30

Family

ID=51570487

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227040760A Active KR102661249B1 (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체
KR1020217037457A Ceased KR20210143932A (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체
KR1020167007277A Active KR102329584B1 (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체
KR1020247013414A Ceased KR20240056664A (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020227040760A Active KR102661249B1 (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체
KR1020217037457A Ceased KR20210143932A (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체
KR1020167007277A Active KR102329584B1 (ko) 2013-09-11 2014-09-11 종양 치료용 항-ｂ7-ｈ1 항체

Country Status (19)

Country Link
US (3) US10336823B2 (enExample)
EP (2) EP3043816B1 (enExample)
JP (5) JP6550053B2 (enExample)
KR (4) KR102661249B1 (enExample)
CN (2) CN105873606B (enExample)
AU (3) AU2014320343B2 (enExample)
BR (1) BR112016005303A2 (enExample)
CA (1) CA2923499A1 (enExample)
DK (1) DK3043816T3 (enExample)
ES (1) ES2749744T3 (enExample)
HU (1) HUE046674T2 (enExample)
IL (5) IL321966A (enExample)
MX (1) MX370818B (enExample)
NZ (2) NZ757060A (enExample)
PL (1) PL3043816T3 (enExample)
RU (1) RU2701327C2 (enExample)
SA (1) SA516370713B1 (enExample)
TW (1) TWI643633B (enExample)
WO (1) WO2015036499A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
BR112016005303A2 (pt) * 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
BR112016027881A2 (pt) * 2014-05-29 2017-10-24 Medimmune Ltd antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
WO2016034718A1 (en) * 2014-09-05 2016-03-10 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
SG10201810615VA (en) 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
JP6826055B2 (ja) 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
CA2983067A1 (en) * 2015-04-23 2016-10-27 Medimmune Limited Combination therapy for non-small cell lung cancer positive for egfr mutation
RS61152B2 (sr) * 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US20190144545A1 (en) * 2016-05-26 2019-05-16 Merck Patent Gmbh PD-1/PD-L1 Inhibitors for Cancer Treatment
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
JP7250764B2 (ja) 2017-08-18 2023-04-03 コセラ バイオサイエンス， インコーポレイテッド Ｔｇ０２の多形形態
CN111971059A (zh) * 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
EP3768713A2 (en) 2018-03-22 2021-01-27 Keires AG Antagonistic pd-1, pd-l1 and lag-3 binding proteins
JP7574198B2 (ja) 2019-01-18 2024-10-28 ドラセン ファーマシューティカルズ インコーポレイテッド Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法
CA3127388A1 (en) * 2019-01-25 2020-07-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
MA55516A (fr) 2019-03-26 2022-02-09 Univ Michigan Regents Agents de dégradation, à petites molécules, de stat3
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
CN114222729A (zh) 2019-06-12 2022-03-22 范德比尔特大学 氨基酸转运抑制剂及其用途
CN114173794A (zh) * 2019-06-25 2022-03-11 希望之城 Pdl1阳性nk细胞癌症治疗
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
WO2021011713A1 (en) 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof
AU2020336381A1 (en) 2019-08-27 2022-03-03 The Regents Of The University Of Michigan Cereblon E3 ligase inhibitors
WO2021055756A1 (en) 2019-09-19 2021-03-25 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
EP4034568A4 (en) * 2019-09-25 2024-02-14 Wuxi Biologics Ireland Limited Novel anti-pd-l1 antibodies
WO2021195481A1 (en) 2020-03-26 2021-09-30 The Regents Of The University Of Michigan Small molecule stat protein degraders
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
CA3213407A1 (en) * 2021-03-26 2022-09-29 Astrazeneca Ab Combination treatments for melanoma
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN101693562A (zh) * 2009-10-21 2010-04-14 山东大学 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂
LT3279215T (lt) * 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
LT2785375T (lt) * 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112016005303A2 (pt) * 2013-09-11 2017-09-12 Medimmune Ltd anticorpos anti-b7-h1 para tratamento de tumores
RS59134B1 (sr) * 2014-05-13 2019-09-30 Medimmune Ltd Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
WO2016034718A1 (en) * 2014-09-05 2016-03-10 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
US20170320954A1 (en) * 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
AU2017257505B2 (en) * 2016-04-25 2020-05-14 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
MX2018013762A (es) * 2016-05-13 2019-03-28 Medimmune Llc Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.

Also Published As

Publication number Publication date
JP2019163269A (ja) 2019-09-26
DK3043816T3 (da) 2019-10-14
KR102329584B1 (ko) 2021-11-22
PL3043816T3 (pl) 2020-03-31
JP7342167B2 (ja) 2023-09-11
HUE046674T2 (hu) 2020-03-30
AU2014320343B2 (en) 2020-05-28
US10336823B2 (en) 2019-07-02
JP6550053B2 (ja) 2019-07-24
EP3043816B1 (en) 2019-08-14
MX370818B (es) 2020-01-08
KR102661249B1 (ko) 2024-04-25
JP2021006537A (ja) 2021-01-21
NZ757060A (en) 2022-07-01
CN112546217B (zh) 2025-04-29
IL274462A (en) 2020-06-30
CN112546217A (zh) 2021-03-26
JP2023166474A (ja) 2023-11-21
KR20220162843A (ko) 2022-12-08
US20160222120A1 (en) 2016-08-04
IL321966A (en) 2025-09-01
MX2016002826A (es) 2016-09-13
SA516370713B1 (ar) 2019-03-10
IL274462B (en) 2022-05-01
CN105873606B (zh) 2020-12-29
AU2020223728A1 (en) 2020-09-17
IL244422A0 (en) 2016-04-21
JP2022065100A (ja) 2022-04-26
AU2024203898A1 (en) 2024-07-04
KR20160044030A (ko) 2016-04-22
WO2015036499A1 (en) 2015-03-19
NZ718821A (en) 2022-07-01
BR112016005303A2 (pt) 2017-09-12
CA2923499A1 (en) 2015-03-19
RU2701327C2 (ru) 2019-09-25
IL313188B1 (en) 2025-08-01
RU2016113341A3 (enExample) 2018-05-30
IL313188B2 (en) 2025-12-01
TWI643633B (zh) 2018-12-11
US20210171639A1 (en) 2021-06-10
EP3043816A1 (en) 2016-07-20
TW201605472A (zh) 2016-02-16
AU2020223728B2 (en) 2024-03-07
EP3656398A1 (en) 2020-05-27
IL292193B1 (en) 2024-07-01
RU2016113341A (ru) 2017-10-16
JP7119037B2 (ja) 2022-08-16
RU2019128452A (ru) 2019-10-24
AU2014320343A1 (en) 2016-04-21
IL292193B2 (en) 2024-11-01
US20190338033A1 (en) 2019-11-07
IL313188A (en) 2024-07-01
KR20210143932A (ko) 2021-11-29
JP2016530323A (ja) 2016-09-29
CN105873606A (zh) 2016-08-17
US11827706B2 (en) 2023-11-28
IL244422B (en) 2020-05-31
US10829557B2 (en) 2020-11-10
ES2749744T3 (es) 2020-03-23
IL292193A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
US11827706B2 (en) Anti-B7-H1 antibodies for treating tumors
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
US20240150469A1 (en) Anti-b7-h1 antibodies for treating tumors
RU2817281C2 (ru) Антитела к b7-h1 для лечения опухолей
HK40030575A (en) Anti-b7-h1 antibodies for treating tumors
HK1226964A1 (en) Anti-b7-h1 antibodies for treating tumors
HK1226964B (en) Anti-b7-h1 antibodies for treating tumors
HK1224560B (zh) 用於治疗肿瘤的抗b7-h1抗体
WO2023164662A1 (en) Treatment of squamous non small cell lung cancer
HK1224560A1 (en) Anti-b7-h1 antibodies for treating tumors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000